Mark your calendar for the next conference in the series, 'Metabolic Approaches to Chronic Liver Disease', taking place March 1-4, 2027 in Keystone, CO, USA.

Metabolic dysfunction-associated steatohepatitis (MASH), a prevalent complication of obesity, is already the most common chronic liver disease and is projected to soon become the leading cause of liver transplantation worldwide. Advancing our understanding of MASH initiation and progression is critical to developing much-needed therapies for at-risk patients. 

This meeting will address key gaps, including: 

• hepatocyte lipid accumulation’s impact on metabolic and regenerative processes? 

• Hepatic and systemic pathways driving liver inflammation and fibrosis 

• Innovative in vitro and animal models for studying MASH 

• Non-invasive biomarkers and imaging tools to monitor disease progression 

Attendees will gain access to the latest science in MASH pathogenesis, and industry perspectives that will inform therapeutic strategies and foster robust academic–industry collaborations to accelerate translational impacts. 

A unique feature of this meeting is its integration of expertise from bioengineering, metal biology, and metabolism with leading clinical insights. This interdisciplinary approach is expected to drive new silico, in vitro, and in vivo models of MASH and ultimately inspire novel treatment strategies. 

Check out the speaker highlights in the video below: